Gazette.govt.nzPursuant to section 20 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the new medicines which were referred to the Minister of Health under the provisions of section 24(5) of the Act and are set out in the Schedule hereto:
Schedule
| Product: | Kanjinti |
| Active Ingredient: | Trastuzumab 60mg |
| Dosage Form: | Powder for infusion concentrate |
| New Zealand Sponsor: | Amgen New Zealand Limited |
| Manufacturer: | Actavis Italy S.p.A, Nerviano, Italy |
| Product: | Kanjinti |
| Active Ingredient: | Trastuzumab 150mg |
| Dosage Form: | Powder for infusion concentrate |
| New Zealand Sponsor: | Amgen New Zealand Limited |
| Manufacturers: | Actavis Italy S.p.A, Nerviano, Italy Amgen Technology (Ireland) Unlimited Company, Dun Laoghaire, Ireland |
| Product: | Kanjinti |
| Active Ingredient: | Trastuzumab 440mg |
| Dosage Form: | Powder for infusion concentrate |
| New Zealand Sponsor: | Amgen New Zealand Limited |
| Manufacturers: | Actavis Italy S.p.A, Nerviano, Italy Amgen Technology (Ireland) Unlimited Company, Dun Laoghaire, Ireland |
Dated this 15th day of August 2022.
CHRIS JAMES, Group Manager, Medsafe, Ministry of Health (pursuant to delegation given by the Minister of Health on 11 September 2013).